Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study (TREATS)

April 22, 2026 updated by: Margaret Burke, Sligo General Hospital

TREATS: Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study

This study is being done to find out if video consultations (telemedicine) can be used to safely and effectively assess and manage skin problems caused by cancer treatments. Instead of always coming to the hospital for a face-to-face appointment, the patient may be able to use thier smartphone or computer to show your skin to a nurse or doctor over a secure video call. the researchers want to see if this is as good as a regular clinic visit, and whether patients and staff are happy with this new way of working.

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

25

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Ireland
    • Sligo
      • Sligo, Sligo, Ireland, f91h684
        • Sligo University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:Participants must meet all of the following criteria:

  • Adult oncology or haematology patients currently receiving systemic anti-cancer therapy (SACT).
  • New-onset dermatologic toxicity consistent with a recognised adverse effect of the administered SACT.
  • Skin toxicity severity graded ≤ Grade 2 in accordance with UKONS assessment criteria.
  • Clinically stable condition not requiring urgent in-person evaluation.
  • Access to, and ability to use, a smartphone or computer with adequate internet connectivity to participate in telemedicine consultations.

Exclusion Criteria: Participants will be excluded if any of the following criteria apply:

  • Skin toxicity graded ≥ Grade 3 according to UKONS assessment criteria.
  • Clinical status requiring urgent or immediate face-to-face medical assessment.
  • Dermatologic toxicity that is atypical, unexpected, or not consistent with known SACT-related adverse effects.
  • Inability to access or effectively use the required telemedicine technology.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Remote tele medicine assessment
use of telemedicine
Other: telem healthassessment
SOC is face to face assessment-this study aims to use telemedecine toassess Treatment related skin disorders

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
time to clinical resolution
Time Frame: 6 weeks
Number of days from first AHOS contact to documented resolution (Grade 0-1).
6 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Escalation in person review
Time Frame: 6 weeks

Proportion of telemedicine patients requiring:

  • Conversion to face-to-face review
  • Emergency department attendance
  • Hospital admission
6 weeks
treatment modification reat
Time Frame: 6 weeks

Proportion of telemedicine patients requiring:

  • Conversion to face-to-face review
  • Emergency department attendance
  • Hospital admission
6 weeks
unscheduled acute contact
Time Frame: 6 weeks
Number of unplanned re-contacts with AHOS
6 weeks
Patient-Reported Endpoints -Quality of Life (QoL) and patient satisfaction
Time Frame: 6 weeks

Instrument:

QLQ administered:

  • Post initial assessment
  • At resolution or week 6
6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sligo General Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2026

Primary Completion (Actual)

April 1, 2026

Study Completion (Estimated)

September 12, 2026

Study Registration Dates

First Submitted

February 27, 2026

First Submitted That Met QC Criteria

March 12, 2026

First Posted (Actual)

March 17, 2026

Study Record Updates

Last Update Posted (Actual)

April 28, 2026

Last Update Submitted That Met QC Criteria

April 22, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1067SUHREC

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rash

Clinical Trials on telem healthassessment

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe